NextCell Pharma AB entered into a strategic collaboration with Fujifilm Irvine Scientific Inc. to combine core competences in mesenchymal stromal cells (MSCs) and raw materials for the life science sector. The collaboration aims to provide researchers and developers in the cell therapy field with an integrated offering of standardized MSC products, optimized culture media, and cryopreservation solutions.

In 2024, NextCell expanded its portfolio by developing a research-use-only umbilical cord MSC product, manufactured using in-house expertise for the commercial market. The collaboration with Fujifilm Irvine Scientific aims to combine this cell product with Fujifilm’s established MSC media and cryopreservation product lines.

Fujifilm is a global developer of high-quality cell culture solutions for the life science and medical markets and is commited to advancing areas such as cell and gene therapy. 

“We have worked closely together to develop this business relationship and are proud to be able to announce this new opportunity to our shareholders,” said Dr Lindsay Davies, CSO at NextCell.

Mathias Svahn, CEO at NextCell, added, “This is a new business venture for NextCell, and we are excited to collaborate with Fujifilm, combining our expertise to build a strong partnership for the future.”